Entropy Neurodynamics Limited Total Liabilities
Entropy Neurodynamics Limited total liabilities. Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has total liabilities worth AU$1.02 Million AUD (≈ $722.06K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ENP asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Entropy Neurodynamics Limited (2018–2026)
Total liabilities of Entropy Neurodynamics Limited from 2018 to 2026. This chart illustrates how Entropy Neurodynamics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Entropy Neurodynamics Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
Entropy Neurodynamics Limited Competitors by Total Liabilities
The table below lists competitors of Entropy Neurodynamics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CLOUDR GROUP LTD.
F:H3L
|
Germany | €1.33 Billion |
|
Wellbiotec Co. Ltd.
KO:010600
|
Korea | ₩11.76 Billion |
|
Remsons Industries Limited
NSE:REMSONSIND
|
India | Rs2.09 Billion |
|
Ocado Group PLC
LSE:OCDO
|
UK | GBX2.60 Billion |
|
Omni-Lite Industries Canada Inc.
V:OML
|
Canada | CA$6.80 Million |
|
Largo Resources Ltd
TO:LGO
|
Canada | CA$182.22 Million |
|
Willowglen MSC Bhd
KLSE:0008
|
Malaysia | RM41.05 Million |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
Turkey | TL931.18 Million |
Liability Composition Analysis (2018–2026)
This chart breaks down Entropy Neurodynamics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ENP total assets.
Liquidity & Leverage Metrics
Entropy Neurodynamics Limited Total Liabilities Ratios Explained
Entropy Neurodynamics Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entropy Neurodynamics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual total liabilities of Entropy Neurodynamics Limited from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$1.02 Million ≈ $722.06K |
+45.96% |
| 2025-06-30 | AU$699.17K ≈ $494.71K |
-61.85% |
| 2024-06-30 | AU$1.83 Million ≈ $1.30 Million |
+4.47% |
| 2023-06-30 | AU$1.75 Million ≈ $1.24 Million |
-63.50% |
| 2022-06-30 | AU$4.81 Million ≈ $3.40 Million |
+85.57% |
| 2021-06-30 | AU$2.59 Million ≈ $1.83 Million |
+69.81% |
| 2020-06-30 | AU$1.53 Million ≈ $1.08 Million |
+442.75% |
| 2019-06-30 | AU$281.00K ≈ $198.83K |
-10.94% |
| 2018-06-30 | AU$315.53K ≈ $223.26K |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more